GLP-1 Pregnancy Washout: 2 Months Before Conception — Why?

The two-month rule is a semaglutide rule, not a GLP-1 rule. Wegovy and Ozempic are the only current labels that tell you to stop a set time before you try to conceive — both say to discontinue “at least 2 months before a planned pregnancy” because semaglutide takes about five to seven weeks to leave the body^[1][3]. Zepbound, Mounjaro, Saxenda and Foundayo publish no pre-conception window at all. What they publish instead is a warning of possible fetal harm and a single instruction: stop when a pregnancy is recognized^[2][11][12]. That gap is not permission to keep taking them into a conception attempt, and it is not a safety ranking. It is a difference in what the manufacturers were required to write down, and it changes how you plan.

The honest summary

• Only semaglutide carries a dated window. Wegovy’s Section 8.3 says to stop “at least 2 months before a planned pregnancy because of the long half-life”^[1]; Ozempic’s says the same thing and points to the long washout period for semaglutide^[3].
• Tirzepatide, liraglutide and orforglipron publish no such number. The phrases “2 months” and “planned pregnancy” do not appear anywhere in the Zepbound, Mounjaro, Saxenda or Foundayo labels. Anyone who tells you the Zepbound label carries a two-month rule is describing a document that does not exist.
• Every one of them still warns about the fetus. Zepbound, Saxenda and Foundayo all say the same sentence: may cause fetal harm, and “When pregnancy is recognized, discontinue”^[2][11][12]. Mounjaro, a diabetes label, says it should be used in pregnancy only where the benefit justifies the risk^[4].
• Pregnancy is not a contraindication on any of these labels. Section 4 on all six lists medullary thyroid carcinoma or MEN 2 and serious hypersensitivity — nothing else. Saxenda’s label records pregnancy being removed from Section 4 in May 2025^[11]. That is a labeling fact, not a green light: the fetal-harm warning and the stop-on-recognition instruction both survived the change.
• Human pregnancy data are limited, not reassuring enough to plan around. The 2026 Hakim meta-analysis of periconceptional exposure^[6] and the 2026 Ozbek safety review^[7] found no clear excess of major malformations, but neither is large enough to rule out a small effect. Neither changes what the labels say.
• An unplanned pregnancy on a GLP-1 is not an emergency decision. Stop the drug, call the prescriber, ask about the manufacturer pregnancy registry, and continue normal prenatal care. The 2025 Drummond review is explicit that inadvertent exposure is not an indication for termination^[5].

What each label actually says

Why semaglutide got a number and the others did not

The reason is pharmacokinetic, and the labels say so out loud. Semaglutide has an elimination half-life of about one week, and the Wegovy label spells out the consequence: the drug “will be present in the circulation for about 5 to 7 weeks” after the last injection^[1]. Two months clears that comfortably. Tirzepatide’s half-life is roughly five to six days^[2][4], liraglutide’s is about 13 hours^[11], and orforglipron’s is 29 to 49 hours^[12]. Those drugs are gone sooner, so no dated window was written. The arithmetic still belongs in your plan even when the label skips it.

Magnitude: % of steady-state semaglutide remaining by week

Run the same model on tirzepatide and five to six days per half-life puts you under 1% of steady state somewhere around week six or seven. Liraglutide is effectively gone in two or three days; orforglipron in about a week and a half. None of that is on a label, and none of it substitutes for a conversation with the prescriber — but it is why a clinician planning a tirzepatide off-ramp usually lands on weeks, not months. See how long Mounjaro stays in your system for the tirzepatide version of this arithmetic.

What the animal data showed

The fetal-harm language on all six labels traces back to reproductive toxicology in animals, not to human outcomes. In pregnant rats given tirzepatide during organogenesis, the Mounjaro label reports fetal growth reductions and fetal abnormalities at clinically relevant exposures^[4]; the semaglutide programs showed embryofetal mortality, structural abnormalities and growth effects in rats, rabbits and cynomolgus monkeys^[3]. Whether those signals translate to humans at therapeutic doses is unknown. The regulatory answer was a warning plus an instruction to stop, and — for semaglutide alone — a date^[5].

What the human pregnancy data look like

The 2026 Hakim systematic review and meta-analysis in the American Journal of Obstetrics and Gynecology pooled observational data on periconceptional GLP-1 exposure and found no statistically significant excess of major congenital malformations against matched controls^[6]. The 2026 Ozbek safety review in Diabetes, Obesity and Metabolism reached the same direction across preconception, pregnancy and lactation^[7]. The 2025 Drummond and Seif review sets out the labeling rationale and the post-marketing experience that shapes maternal-fetal medicine practice today^[5].

Three caveats keep those findings from being a green light. Samples are modest, so small absolute differences cannot be excluded. Most captured exposures are early, first-trimester and accidental rather than deliberate. And the underlying populations — obesity, type 2 diabetes — carry their own obstetric risk, which muddies any causal read. Miscarriage is the question patients ask most, and the same confounding applies: no study has shown a GLP-1-specific mechanism for early loss at therapeutic doses in humans.

The oral-contraceptive interaction, and who it applies to

Tirzepatide and orforglipron slow gastric emptying enough to cut exposure to oral contraceptives. The Zepbound and Mounjaro labels tell patients on oral contraceptives to switch to a non-oral method, or add a barrier method, for four weeks after starting and four weeks after every dose increase^[2][4]. Foundayo says the same thing with a 30-day window^[12]. Non-oral hormonal methods are not affected. Semaglutide does not produce an interaction of the same size^[8]. Our full write-up is in the Mounjaro and Zepbound birth control warning and GLP-1s and contraception.

This cuts both ways for someone planning a pregnancy. While you are still on the drug and not ready to conceive, a pill alone may not be doing the job you think it is. Once you stop, the interaction stops mattering — but the weeks before you stop still need covering.

Weight regain after stopping

STEP 4 randomized patients who had already reached steady weight loss on semaglutide 2.4 mg at week 20 either to continue or to switch to placebo for 48 more weeks^[9]. The continuing group lost about another 7.9% of body weight; the placebo group regained about 6.9%. Regain starts almost immediately. For pre-conception planning that matters in a practical way: the weight you see on the last day of treatment is not where you will be when you conceive. Expect upward drift through the off-drug weeks and into early pregnancy, and plan the protein and resistance work that slows it — the muscle loss prevention protocol applies to any off-ramp. How that regain relates to gestational diabetes risk is covered in gestational diabetes, BMI and GLP-1 timing.

For patients with polycystic ovary syndrome there is a second effect worth naming. Carmina and Longo reported restored ovulatory cycles in women with obesity and PCOS treated with semaglutide^[10]. Fertility can improve on a GLP-1, which means an unplanned pregnancy becomes more likely in exactly the group that assumed it could not happen. Contraception has to keep up with that. The broader picture is in GLP-1s, pregnancy, PCOS and fertility.

A planning timeline that works for either drug

1. About four months out. Pre-conception visit with an OB-GYN or maternal-fetal medicine specialist. Agree on the conception window, and start folic acid 400 mcg daily — folate stores need weeks to saturate before the neural tube closes.
2. About three months out. Take stock of weight and metabolic numbers while still on treatment, with the understanding that they will move once you stop.
3. Two months out, on semaglutide. This is the labeled stop date for Wegovy and Ozempic^[1][3]. Stop here.
4. On tirzepatide, liraglutide or orforglipron, there is no labeled date — set one with the prescriber. The half-lives are shorter, so the clearance interval is shorter, but the decision is clinical rather than something you can read off the carton. Do not assume the semaglutide number transfers, and do not assume no number means no wait.
5. Through the off-drug weeks. Keep the prenatal vitamin going. If you are on tirzepatide or orforglipron and still using an oral contraceptive, keep the backup method in place until you are ready to try.
6. If pregnancy comes sooner than planned. Stop the GLP-1, contact the prescriber, ask about enrolling in the manufacturer’s pregnancy registry, and continue routine prenatal care. Inadvertent exposure is not an indication for termination^[5].

Breastfeeding

No label in the table has human milk data. Wegovy and Ozempic report no information on semaglutide in human milk, on the breastfed infant, or on milk production, with the drug detected in rat milk^[1][3]; the tirzepatide and orforglipron labels take the same posture^[2][12]. The 2026 Ozbek review confirms the absence of solid human lactation evidence across the class^[7]. In practice, treatment resumes after weaning rather than during it. Postpartum GLP-1 use covers the timing question in more detail.

Related research and tools

• GLP-1, pregnancy, PCOS and fertility — the broader companion to this timing piece
• BHRT + GLP-1 in perimenopause — hormone replacement stacking in midlife patients
• GLP-1 muscle loss prevention protocol — the protein and training plan for any off-ramp
• GLP-1 protein calculator — carry a workable target into the off-drug weeks